Page 1 of 20



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN 10/644,783

APPLICANT
Nancy C. LAN

FILING DATE GROUP

				August 21, 2003	t t	1614	
			U.S. PA	PENT DOCUMENTS			
EXAMINER INIZTAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DAT
(7)	AA1	4,024,175	05/17/1977	Satzinger et al.			12/31/1975
7	AB1	4,087,544	05/02/1978	Satzinger et al.			04/28/1977
	AC1	4,602,017	07/22/1986	Sawyer et al.]	02/27/1984
	AD1	4,894,476	01/16/1990	Butler et al.			05/02/1988
	AE1	5,025,035	06/18/1991	Wallace			10/12/1990
	AF1	5,179,109	01/12/1993	Kamenka et al.			06/21/1990
	AG1	5,236,957	08/17/1993	Dostert et al.			01/25/1991
	AH1	5,256,669	10/26/1993	Askanazi et al.			08/07/1992
	AI1	5,330,515	07/19/1994	Rutecki et al.			06/17/1992
	AJ1	5,446,066	08/29/1995	Varasi et al.			03/22/1994
121	AK1	5,449,692	09/12/1995	Varasi et al.			03/22/1994
01				ATENT DOCUMENTS			I
EXAMINER		<u> </u>	T				·
NITVAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATIO
7	AL1	WO 96/40628	12/19/1996	WIPO			Yo
	AM1	WO 97/05102	02/13/1997	WIPO			Y
	AN1	WO 98/07447	02/26/1998	WIPO			Y
	A01	WO 98/08842	03/05/1998	WIPO			Y
	AP1	WO 98/19674 A2	05/14/1998	WIPO			Y
) \		OTHER (Includi	ng Author, Ti	tle, Date, Pertinent P	ages, etc	.)	
(B)	AR	Neuropathy in Medical Asso	n Patients Wi	Gabapentin for the S th Diabetes Mellitus," mber 1998) ic Pain: An Overview," ed., IASP Press, Seatt	JAMA 280	:1831-1836,	The Americ
6	АТ			Controlled Trial of J. Med. 330:585-591, T	he Massa	chusetts Med	
XAMINER		Brl				CONSIDERED	
raw line th	rough o	citation if not in	idered, wheth conformance	er or not citation is and not considered. I	in confor nclude co	mance with opy of this	MPEP 609. form with
		to Applicant. DC1:197764:1			··	· · · · · · · · · · · · · · · · · · ·	

::ODMA\MHODMA\SKGF_DC1;197764;1

Page 2 of 20



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

					August 21, 2003		GROUP	
				U.S. PAT	ENT DOCUMENTS			
EXAMINER INPTRAL		DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DAT
13	AA2	5,6	60,861	08/26/1997	Jao et al.			05/12/1995
	AB2	5,7	12,277	01/27/1998	Nakamura-Craig et al.			07/15/1996
	AC2	5,7	41,818	04/21/1998	Dimmock			06/07/1995
	AD2	5,8	91,849	04/06/1999	Amstutz et al.			11/07/1997
. \	AE2	5,90	05,069	05/18/1999	Borsook et al.			01/26/1998
	AF2	5,9	42,510	08/24/1999	Floyd et al.			06/20/1996
	AG2	6,1	13,915	09/05/2000	Aoki et al.			10/12/1999
	AH2	6,18	80,624 B1	01/30/2001	Hill			02/25/1999
	AI2	6,18	87,338 B1	02/13/2001	Caruso et al.	ļ.		02/22/1999
. (AJ2	6,20	07,685 B1	03/27/2001	Lallement et al.			01/11/1999
G'	AK2	6,24	42,488 B1	06/05/2001	Bueno et al.			05/09/2000
7				FOREIGN P	ATENT DOCUMENTS			·
XAMINER NITLAL		DOCU	JMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATIO
(3)	AL2	FR 2	2 756 738	06/12/1998	France			X Ye
	AM2	wo s	98/28255	07/02/1998	WIPO			Ye 1
	AN2	wo s	98/19674 A3	07/16/1998	WIPO			Ye
	A02	WO S	8/43964	10/08/1998	WIPO			Ye
(ξ)	AP2	WO 9	8/47869	10/29/1998	WIPO			Ye N
		02	THER (Including	g Author, Til	le, Date, Pertinent Pag	es, etc	.)	
Q	AR	<u>2</u>	Beydoun, A., Modalities," (October 1999	Epilepsia 4	ic Neuralgia: Role of (40(Suppl. 6):S51-S56,	Gabapen Lippinco	in and Oth ott William	er Treatmen s & Wilkin
	AS	2	Blinder, B.J. 169:39-40, BM	, et al., "A My Publishing	dvances in Mood Stabiliz (1998)	ing Med	ications," [Vest. J. Med
Q	AT	2	motor dysfund	ction: correl	ive NMDA NR2B antagonists ation with restricted lacology 38:611-623, Perg	ocalisa	tion of NR2	B subunit :
KAMINER		(f)				Taxan c	ONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
::ODMA\MHODMA\SKGF_DC1;197764;1



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783	
APPLICANT Nancy C. LAN		
FILING DATE	GROUP 1614	

					August 21, 2003		614	
				U.S. PAT	ENT DOCUMENTS			
EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
(4)	AA3		81,211 B1	08/28/2001	Cai et al.			09/21/2000
	AB3	1	90,986	09/18/2001	Murdock et al.			06/29/1998
	AC3	6,32	26,374 B1	12/04/2001	Magnus et al.			06/18/1999
(3)	AD3	6,3	26,385 Bl	12/04/2001	Wickenden et al.			08/04/2000
. 	AE							
	AP							
	AG							
	АН							
	AI					<u> </u>		
	AJ	ļ						
	AK							<u> </u>
				POREIGN PA	ATENT DOCUMENTS			
XAMINER NIT YAL	<u> </u>	DOCI	JMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATIO
6	AL3	wo s	99/12537	03/18/1999	WIPO			Y e
	АМ3	wo s	99/26614	06/03/1999	WIPO .	ļ		Ye
	AN3	DE I	198 02 327 A1	07/29/1999	Germany			Ye X N
Δ	АОЗ	WO S	99/37296	07/29/1999	WIPO			Ye N
	АРЗ	WO S	99/39712	08/12/1999	WIPO			Ye N
		07	THER (Including	g Author, Ti	tle, Date, Pertinent Pag	ges, etc	.)	
8	AR	<u>3</u>	of other age	ents in a m	oprotective properties on ouse model of focal constant of Stockton Press (1995)			
	AS	<u>3</u>			, D.J., "3-Substituted G w," Med. Res. Rev. 19:1			
D	AT	<u>3</u>	Buchan, A.M., Stroke Trials Heart Associa	Than NMDA An	IPA Antagonists: Do They tagonists?," Supplement	Hold M	ore Promise c <i>e 24</i> :I148-I	for Clinica 152, America
KAMINER		L				DATE	CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in-conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

::ODMA\MHODMA\SKGF_DC1;197764;1



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

DOCU	JMENT NUMBER	U.S. PAT	NAME	CLASS	SUB-CLASS	FILING	DATE
AAB AC AD AE AF	JMENT NUMBER	DATE	NAME	CLASS		FILING	DATE
AB AC AD AE AF					·		
AC AD AE AF					 ·	ļ	
AD AE AF							
AE AF AG				L L		 	
AF AG					ļ		
AG .					ļ	ļ	
AH.	 				ļ		
		<u> </u>			ļ		
VI.		ļ			ļ		
J	 .				-	ļ	
AK .					<u> </u>	<u> </u>	
	· · · · · · · · · · · · · · · · · · ·	FOREIGN PA	ATENT DOCUMENTS		<u> </u>	Т	
DOCU	JMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLA	
AL4 WO S	99/44610	09/10/1999	WIPO		<u> </u>		Ye N
M4 WO S	99/61408	12/02/1999	WIPO			×	Ye N
N4 WO	00/02562	01/20/2000	WIPO			· ·	Ye N
104 WO (00/02592	01/20/2000	WIPO				Ye N
1P4 WO (00/57877	10/05/2000	WIPO				Ye N
0'	THER (Includin	g Author, Ti	tle, Date, Pertine	nt Pages, et	c.)		
R <u>4</u>				geminal neur	algia," <i>Pait</i>	1 60:229	-231
s <u>4</u>	qabapentin i	n the treatm	ment of trigeminal				
т 4	antiarrhythm:	ics and antic	convulsants," Tren				
		4.5		DATE	CONSIDERED		
ALL AMMAN RR R	DOCI 4 WO 9 14 WO 9 14 WO 9 14 WO 9 14 WO 10 14 WO 10 14 WO 10 15 WO 10 16 WO 10 17 WO 10 18 WO	DOCUMENT NUMBER 4 WO 99/44610 4 WO 99/61408 4 WO 00/02562 4 WO 00/02592 Canavero, S. Elsevier Science Publication of the Canada Acada 4 Catterall, W. antiarrhythmis Science Publication of the Canada Acada Catterall, W. antiarrhythmis Science Publication of the Catterall of the Catteral of the Cat	FOREIGN P. DOCUMENT NUMBER DATE 4 WO 99/44610 09/10/1999 4 WO 09/61408 12/02/1999 4 WO 00/02562 01/20/2000 A WO 00/02592 01/20/2000 OTHER (Including Author, Time of the company of the company of Neuron antiarrhythmics and antiarrhythmics an	FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY WO 99/44610 09/10/1999 WIPO WO 00/02562 01/20/2000 WIPO WO 00/02592 01/20/2000 WIPO OTHER (Including Author, Title, Date, Pertine Canavero, S., et al., "The riddle of tri Elsevier Science B.V. (1995) Carrazana, E.J., and Schachter, S.C., "Jabary Science Publishers B.V. (1987) Catterall, W.A., "Common modes of drug activantial if reference considered, whether or not citation	FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS 4 WO 99/44610 09/10/1999 WIPO 4 WO 00/02562 01/20/2000 WIPO OTHER (Including Author, Title, Date, Pertinent Pages, et Elsevier Science B.V. (1995) Carrazana, E.J., and Schachter, S.C., "Alternative gabapentin in the treatment of trigeminal neuralgia," American Academy of Neurology (April 1998) Catterall, W.A., "Common modes of drug action on Na+ cha antiarrhythmics and anticonvulsants," Trends Pharmacol Science Publishers B.V. (1987) DATE	POREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS A WO 99/44610 09/10/1999 WIPO A WO 00/02562 01/20/2000 WIPO A WO 00/02592 01/20/2000 WIPO OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Canavero, S., et al., "The riddle of trigeminal neuralgia," Pair Elsevier Science B.V. (1995) Carrazana, E.J., and Schachter, S.C., "Alternative uses of lam gabapentin in the treatment of trigeminal neuralgia," Neurology American Academy of Neurology (April 1998) Catterall, W.A., "Common modes of drug action on Na+ channels: local antiarrhythmics and anticonvulsants," Trends Pharmacol. Sci. 8:57-Science Publishers B.V. (1987) DATE CONSIDERED	FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLA A WO 99/44610 09/10/1999 WIPO A WO 00/02562 01/20/2000 WIPO A WO 00/02562 01/20/2000 WIPO OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Canavero, S., et al., "The riddle of trigeminal neuralgia," Pain 60:229. Elsevier Science B.V. (1995) Carrazana, E.J., and Schachter, S.C., "Alternative uses of lamotrigine gabapentin in the treatment of trigeminal neuralgia," Neurology 50:1192, American Academy of Neurology (April 1998) Catterall, W.A., "Common modes of drug action on Na+ channels: local anesthet antiarrhythmics and anticonvulsants," Trends Pharmacol. Sci. 8:57-65, Else Science Publishers B.V. (1987) DATE CONSIDERED DATE CONSIDERED

Page 5 of 20

OIPE DN 25 200 CE

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1483.0370003/JMC/THN
APPLICANT
APPLICANT

Nancy C. LAN

FILING DATE GROUP
August 21, 2003 1614

					August 21, 2003		1614	
				U.S. PAT	ENT DOCUMENTS			
EXAMINER INITIAL		DOC	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
	AB							·
	AC	ļ						ļ
	AD							
	AE	<u> </u>						
	AF							
	AG	ļ						
	AH							
	AI	<u> </u>						
•	AJ	↓						
	AK	<u></u>						
	 	_		FOREIGN P	ATENT DOCUMENTS			·
EXAMINER INITIAL	•	DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATIO
<u>(4)</u>	AL5	EP 1	L 083 164	03/14/2001	Europe			Ye N
	АМ							Ye
	AN							Ye N
	AO							Ye N
	AP							Ye N
		02	THER (Includin	g Author, Ti	tle, Date, Pertinent	Pages, etc	.)	
3	AR	<u>5</u>			oxins That Act on Vo. . Rev. Pharmacol. Tox			
	AS	<u>5</u>			ure and Function of merican Association (
	АТ	<u>5</u>	Chapman, V., neuronal res Science B.V.	ponses in sp	ects of systemic cark pinal nerve ligated	pamazepine rats," <i>Pa</i>	and gabapen	tin on spina 72, Elsevie
EXAMINER	' 		2/			DATE	CONSIDERED	
XAMINER: 1	nitial	if/re	eference consi	dered, wheth	er or not citation is			MPEP 609

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

^{::}ODMA\MHODMA\SKGF_DC1;197764;1

Page 6 of 20



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783	
APPLICANT Nancy C. LAN		
FILING DATE	GROUP	
August 21, 2003	1614	

DOCUMENT NUMBER DATE NAME CLASS SUB-CLASS FILING I AB AC AD AC AD AE AF AG AR AF AG AN AI AJ AI AJ AN COMMINER OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Creveling, C.R., et el., "Batrachotoxin-Induced Depolarization From Guping Certain Cortex," Mol. Pharmacol. 23:350-358, The American Society Pharmacology and Experimental Therapeutics (1983) AS CZUCZWAT, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," Polish Pharmacol. 23:35-68, Polish Academy of Sciences (2001) AT SESSION OF THE CONSIDERED CARRAGE ANINER DATE CONSIDERED CARRAGE ANINER DATE CONSIDERED CARRAGE ANINER DATE CONSIDERED CARRAGE SITE MORP 609 ANINER: Initial if reference considered, whether or not citation is in conformance with MEPP 609						August 21, 2003		1614	
DOCUMENT NUMBER DATE NAME CLASS SUB-CLASS FILING I AB AC AD AC AD AE AF AG AR AF AG AN AI AJ AI AJ AN COMMINER OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Creveling, C.R., et el., "Batrachotoxin-Induced Depolarization From Guping Certain Cortex," Mol. Pharmacol. 23:350-358, The American Society Pharmacology and Experimental Therapeutics (1983) AS CZUCZWAT, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," Polish Pharmacol. 23:35-68, Polish Academy of Sciences (2001) AT SESSION OF THE CONSIDERED CARRAGE ANINER DATE CONSIDERED CARRAGE ANINER DATE CONSIDERED CARRAGE ANINER DATE CONSIDERED CARRAGE SITE MORP 609 ANINER: Initial if reference considered, whether or not citation is in conformance with MEPP 609					U.S. PA	PENT DOCUMENTS			
ARINER AB AC AC AC AC AC AC AC AC AC	EXAMINER INITIAL		DOC	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DAT
AC AD AE AE AF AG AH AG AH AI AJ AJ AK FOREIGN PATENT DOCUMENTS CAMINER AND OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Creveling, C.R., et al., "Batrachotoxin-Induced Depolarization Guerrance View Pharmacology and Experimental Therapeutics (1983) AS 6 Pharmacology and Experimental Therapeutics (1983) AS 6 Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," Polish Pharmacol. 3135-68, Polish Academy of Sciences (2001) AT S De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Cert Anticonvulsants in DBA/2 Mice," Eur. J. Pharmacol. 349:179-185, Elsevier Sciences (1988) AMNINER: Initial if Teference considered, whether or not citation is in conformance with MEPP 609.		AA							
AB AE AF AG AG AH AI AI AJ AX FOREIGN PATENT DOCUMENTS CAMINER HITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLAT AL AM AN AN AN AN AN AN AN AN AN		AB							
AE AF AG AG AH AI AI AJ AK FOREIGN PATENT DOCUMENTS CAMINER HITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLAT COUNTRY CLASS SUB-CLASS TRANSLAT AN AN AN AN AN AN AN AN AN		AC	1						<u> </u>
AF AG AH AI AJ AX FOREIGN PATENT DOCUMENTS GAMINER WITTAL AD AN AN AN AN AN AN AN AN AN		AD	—		 				ļ
AG AH AI AJ AX AK FOREIGN PATENT DOCUMENTS CAMINER NTITAL AD COUNTRY CLASS SUB-CLASS TRANSLAT AL AM AN AN AN AN AN AN AN AN AN	·								
AH AI AJ AK POREIGN PATENT DOCUMENTS ANITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLAT AL AM AN AN AN AO AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Creveling, C.R., et al., "Batrachotoxin-Induced Depolarization ['M'] Batrachotoxinin-A 200-Benzoate Binding in a Vesicular Preparation from Gu Pig Cerebral Cortex, "Mol. Pharmacol. 23:350-358, The American Society Pharmacology and Experimental Therapeutics (1983) AS 6 Czuczwar, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate Adjuvant Antiepleptic Drugs in Experimental Models of Epilepsy," Polish Pharmacol. 53:65-68, Polish Academy of Sciences (2001) AT 6 De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Cert Anticonvulsants in DBA/2 Mice," Eur. J. Pharmacol. 349:179-185, Elsevier Sciences (1998)			-}						
ANIMER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. ANIMER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. ANIMER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. ANIMER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. ANIMER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. ANIMER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.			+		 				
ANNINER AN AN AN AN AN AN AN AN AN A			+						
FOREIGN PATENT DOCUMENTS CAMINER NITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLAT AL AM AN AO OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Creveling, C.R., et al., "Batrachotoxin-Induced Depolarization ['M'] Batrachotoxinin-A 200-Benzoate Binding in a Vesicular Preparation from Gupig Cerebral Cortex," Mol. Pharmacol. 23:350-358, The American Society Pharmacology and Experimental Therapeutics (1983) AS Czuczwar, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," Polish Pharmacol. 53:65-68, Polish Academy of Sciences (2001) De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Cert Anticonvulsants in DBA/2 Micc," Eur. J. Pharmacol. 349:179-185, Elsevier Sciences (1998) CAMINER: Initial if reference considered, whether or not citation is in conformance with MPRP 608			+-		 	<u> </u>	_	 	
AMINER FOREIGN PATENT DOCUMENTS CAMINER AL AD COUNTRY CLASS SUB-CLASS TRANSLAT COUNTRY CLASS SUB-CLASS TRANSLAT COUNTRY CLASS SUB-CLASS TRANSLAT COUNTRY CLASS SUB-CLASS TRANSLAT AN AN AN AN AN AN Creveling, C.R., et al., "Batrachotoxin-Induced Depolarization ('H)Batrachotoxinin-A 200-Benzoate Binding in a Vesicular Preparation from Gu Pig Cerebral Cortex," Mol. Pharmacol. 23:350-358, The American Society Pharmacology and Experimental Therapeutics (1983) AS Czuczwar, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," Polish Pharmacol. 53:65-68, Polish Academy of Sciences (2001) De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Cert Anticonvulsants in DBA/2 Mice," Eur. J. Pharmacol. 349:179-185, Elsevier Sciences (1998) CAMINER: Initial if Teference considered, whether or not citation is in conformance with MPRP 609	-		1-						
AMINER NITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLAT CLASS SUB-CLASS TRANSLAT CLASS SUB-CLASS TRANSLAT CLASS SUB-CLASS TRANSLAT AN A		124			POPETCH P	ATENT DOCUMENTS			
OCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLAT AL AM AN AN AO OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Creveling, C.R., et al., "Batrachotoxin-Induced Depolarization (PH) Batrachotoxinin-A 20α-Benzoate Binding in a Vesicular Preparation from Gu. Pig Cerebral Cortex," Mol. Pharmacol. 23:350-358, The American Society Pharmacology and Experimental Therapeutics (1983) AS 6 Czuczwar, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," Polish Pharmacol. 53:65-68, Polish Academy of Sciences (2001) AT 6 De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Cert Anticonvulsants in DBA/2 Mice," Eur. J. Pharmacol. 349:179-185, Elsevier Sciences (1998) AMINER: Initial if reference considered, whether or not citation is in conformance with MPRP 609	EXAMINER	1	T		10.00.00.1	T DOCUMENTO		T	
AM AN AN AN AN AN AN AN AN AN	INITIAL		DOCI	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATIO
AN AO AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Creveling, C.R., et al., "Batrachotoxin-Induced Depolarization (Pil) Batrachotoxinin-A 200-Benzoate Binding in a Vesicular Preparation from Gupig Cerebral Cortex," Mol. Pharmacol. 23:350-358, The American Society Pharmacology and Experimental Therapeutics (1983) AS 6 Czuczwar, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," Polish Pharmacol. 53:65-68, Polish Academy of Sciences (2001) AT 6 De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Cert Anticonvulsants in DBA/2 Mice," Eur. J. Pharmacol. 349:179-185, Elsevier Sciences (1998) AMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609		AL				•			Ye N
OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Creveling, C.R., et al., "Batrachotoxin-Induced Depolarization (PH)Batrachotoxinin-A 200-Benzoate Binding in a Vesicular Preparation from Gu: Pig Cerebral Cortex," Mol. Pharmacol. 23:350-358, The American Society Pharmacology and Experimental Therapeutics (1983) Czuczwar, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," Polish Pharmacol. 53:65-68, Polish Academy of Sciences (2001) De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Cere Anticonvulsants in DBA/2 Mice," Eur. J. Pharmacol. 349:179-185, Elsevier Sciences (1998) CAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609		AM							Ye
OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Creveling, C.R., et al., "Batrachotoxin-Induced Depolarization (PH)Batrachotoxinin-A 200-Benzoate Binding in a Vesicular Preparation from Gu: Pig Cerebral Cortex," Mol. Pharmacol. 23:350-358, The American Society Pharmacology and Experimental Therapeutics (1983) Czuczwar, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," Polish Pharmacol. 53:65-68, Polish Academy of Sciences (2001) De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Cere Anticonvulsants in DBA/2 Mice," Eur. J. Pharmacol. 349:179-185, Elsevier Sciences (1998) CAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609		AN							Yе
OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Creveling, C.R., et al., "Batrachotoxin-Induced Depolarization (2H) Batrachotoxinin-A 200-Benzoate Binding in a Vesicular Preparation from Gurpig Cerebral Cortex," Mol. Pharmacol. 23:350-358, The American Society Pharmacology and Experimental Therapeutics (1983) AS 6 Czuczwar, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," Polish Pharmacol. 53:65-68, Polish Academy of Sciences (2001) De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Cert Anticonvulsants in DBA/2 Mice," Eur. J. Pharmacol. 349:179-185, Elsevier Sciences (1998) CAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609								<u> </u>	Ye
OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Creveling, C.R., et al., "Batrachotoxin-Induced Depolarization [3] Batrachotoxinin-A 20α-Benzoate Binding in a Vesicular Preparation from Gurig Cerebral Cortex," Mol. Pharmacol. 23:350-358, The American Society Pharmacology and Experimental Therapeutics (1983) AS 6 Czuczwar, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," Polish Pharmacol. 53:65-68, Polish Academy of Sciences (2001) De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Cert Anticonvulsants in DBA/2 Mice," Eur. J. Pharmacol. 349:179-185, Elsevier Sciences (1998) CAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609	.	AO	<u> </u>						· Ye
Creveling, C.R., et al., "Batrachotoxin-Induced Depolarization (3H)Batrachotoxinin-A 200-Benzoate Binding in a Vesicular Preparation from Guring Cerebral Cortex," Mol. Pharmacol. 23:350-358, The American Society Pharmacology and Experimental Therapeutics (1983) Czuczwar, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," Polish Pharmacol. 53:65-68, Polish Academy of Sciences (2001) De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Cert Anticonvulsants in DBA/2 Mice," Eur. J. Pharmacol. 349:179-185, Elsevier Sciences (1998) CAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609		AP	<u></u>						N N
AR 6 [3H]Batrachotoxinin-A 20α-Benzoate Binding in a Vesicular Preparation from Guing Cerebral Cortex," Mol. Pharmacol. 23:350-358, The American Society Pharmacology and Experimental Therapeutics (1983) Czuczwar, S.J., and Przesmycki, K., "Felbamate, Gabapentin and Topiramate Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy," Polish Pharmacol. 53:65-68, Polish Academy of Sciences (2001) De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Cerebral Anticonvulsants in DBA/2 Mice," Eur. J. Pharmacol. 349:179-185, Elsevier Sciences (1998) CAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.			07	THER (Includin	g Author, Ti	tle, Date, Pertinent I	Pages, etc	.)	
AS 6 Adjuvant Antiepileptic Drugs in Experimental Models of Epilepsy, " Polish Pharmacol. 53:65-68, Polish Academy of Sciences (2001) De Sarro, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Cert Anticonvulsants in DBA/2 Mice," Eur. J. Pharmacol. 349:179-185, Elsevier Sciences (1998) DATE CONSIDERED, TAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.		AR	<u>6</u>	(3H)Batrachot Pig Cerebral	oxinin-A 20α Cortex," <i>h</i>	-Benzoate Binding in a fol. Pharmacol. 23:35	Vesicular 0-358, Th	Preparatio	n from Guine
AT 6 Anticonvulsants in DBA/2 Mice, " Eur. J. Pharmacol. 349:179-185, Elsevier Scientific (1998) DATE CONSIDERED DATE CONSIDERED CAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.		AS	<u>6</u>	Adjuvant Ant	iepileptic [Drugs in Experimental	Models o	entin and T of Epilepsy	Copiramate a
AMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609		AT	<u>6</u>	Anticonvulsa					
AMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.	XAMINER			RI			DATE (CONSIDERED	
	XAMINER:	(nitia)	if r	eference const	dered wheth	er or not ditation is	in confor	mance with	MDED 600
aw line through citation if not in conformance and not considered. Include copy of this form with ext communication to Applicant.	raw line th	rough	citat:	ion if not in	conformance	and not considered.	Include co	py of this	form with

Page 7 of 20



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

					FILING DATE August 21, 2003		GROUP 1614	
				U.S. P	ATENT DOCUMENTS		_	
EXAMINER INITIAL		DOCI	JMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
	AB						1	
	AC	1						
	AD	1		ĺ				
_	AE							
	AF							
	AG							
	AH							
	AI			1				
•	AJ							
	AK							
	*******	A		FOREIGN	PATENT DOCUMENTS			<u> </u>
EXAMINER								
INITIAL	-	DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATIO
	AL							Ye N
	AM							Ye N
	AN							Ye N
	AO							Ye N
								Ye
	AP		WPD (T)14-	- 3.455 5	itle, Date, Pertine			N
G	AR	7	Denicoff, K.	D., et al., ctice Survey	"Efficacy of Carbam ,," J. Clin. Psychia	azepine Compa	red With Ot	her Agents: Postgraduat
	AS	7			Drug Therapy: New An setts Medical Societ		Orugs," New	Engl. J. Med
Q	АТ	<u>7</u>	amitriptylin	e, block bot	"Gabapentin and th static and dynami in the rat," <i>Pain 80</i>	c components	of mechanic	al allodyni
			i					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. ::ODMA\MHODMA\SKGF_DC1;197764;1

Page 8 of 20



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783	
APPLICANT Nancy C. LAN		
FILING DATE	GROUP	

				U.S. 1	PATENT DOCUMENTS				
EXAMINER		T		T	TAIBLE DOCUMENTS			T	
INITIAL	_	DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
	AA			 			ļ	<u> </u>	
	AB	-		ļ				 	
	AC	- 		 			 	<u> </u>	
-	AD	-		 			 	.	
	AE			 					
	AF			 				· · · · · · · · · · · · · · · · · · ·	
·	AG	+		1					
	HA I	-		 			 		
	AJ			 	 		 	 	
	AK	+		 			<u> </u>		
•	JAK	_1		PODRICH	DAMPIM DOGGERATIO	1	 	<u> </u>	
EXAMINER	η	T	<u></u>	FOREIGN	PATENT DOCUMENTS	·	Ţ		
INITIAL		DOCT	UMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
	AL							Yes No	
	AM							Yes	
	All	+			-		 	No Yes	
*	AN		*					No.	
	AO							Yes No	
	AP							Yes No	
	1	07	THER (Includin	g Author.	Title, Date, Pert	inent Pages, etc)	1 10	
Q	AR	<u>8</u>	Goldberg, I.	, and Gree	n, B., "Focus on rom http://www.p	Gabapentin," F	ocus 8:1-6.	Priory Lodge	
	AS	8	Graham, S.H., et al., "A Dose-Response Study of Neuroprotection Using the AMPA Antagonist NBQX in Rat Focal Cerebral Ischemia," J. Pharmacol. Exp. Therap. 276:1-4, Williams & Wilkins (1996)						
G	AT	8	Voltage-Deper	ndent Sodi	"Neuroprotective um Channels, BW ll. Exp. Therp. 2	619C89, in Rat	Middle Cer	ebral Arterv	
EXAMINER		The state of the s	21			DATE	CONSIDERED	,	
RXAMINPD.	Initial		eference core	dared when	thou ou not office		1400	WDDD 600	
Draw line t next commun	hrough ication	citat: to Ap	ion if not in pplicant.	conformanc	ther or not citate and not conside	ered. Include co	rmance with opy of this	MPEP 609. form with	
: ODMA \MHODM	A\SKGF	DC1;19	97764:1		· · · · ·				

Page 9 of 20



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783	
APPLICANT Nancy C. LAN		
FILING DATE	GROUP	

U.S. PATENT DOCUMENTS												
EXAMINER U.S. PAIRNI DOCUMENTS												
INITIAL	_	DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE				
	AA	4	•	ļ								
	AB	-										
	AC	↓	 									
	AD			<u> </u>								
, 	AE	 										
	AF	—	· · · · · · · · · · · · · · · · · · ·									
•	AG	-										
_ ,	АН	 		<u> </u>								
	AI	 										
	AJ	.										
	AK						<u> </u>					
-				FOREIGN F	PATENT DOCUMENTS							
EXAMINER INITIAL		DOCI	JMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION				
	AL							Yes No				
	AM		· · · · · · · · · · · · · · · · · · ·					Yes No				
	AN							Yes				
,	AO	1						No Yes				
		 						No Yes				
	AP	<u> </u>		<u> </u>	<u> </u>			No				
		1 07	THER (Includin	g Author, Ti	tle, Date, Pertinent P	ages, etc	.)					
\bigcirc	AR	<u>9</u>	Model of Fam	ilial Amyotr	of Vitamin E, Riluzol cophic Lateral Sclerosi sociation (1996)	e, and Gal is," <i>Ann</i> .	oapentin in Neurol. 39:	a Transgenic 147-157, The				
	AS	<u>9</u>	Hamill, O.P., et al., "Improved Patch-Clamp Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches," Pfluegers Arch 391:85-100, Springer International (1981)									
	Hoekstra, M.S., et al., "Chemical Development of CI-1008, an Enantiomerically Pure Anticonvulsant," Org. Process Res. Dev. 1:26-38, American Chemical Society and Royal Society of Chemistry (1997)											
EXAMINER		Je	21 _			DATE C	CONSIDERED 1	of of				
EXAMINER: : Draw line th	Initial hrough	ix re	EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with									

Page 10 of 20



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE August 21, 2003	GROUP 1614

				U.S. P	ATENT DOCUMENTS				
EXAMINER INITIAL		DOCI	UMENT NUMBER	DATE	NAME		CLASS	SUB-CLASS	FILING DATE
	AA								
	AB	<u> </u>							ļ
	AC							ļ	<u> </u>
	AD								ļ
•	AE	 		ļ					
	AF			ļ					ļ
•	AG	 		ļ					
	АН								
	AI			ļ					
	AJ								
	AK								
				FOREIGN	PATENT DOCUMENTS	S		<u> </u>	
EXAMINER INITIAL		DOCT	UMENT NUMBER	DATE	COUNTRY		CLASS	SUB-CLASS	TRANSLATION
	AL								Yes No
	AM								Yes No
	AN	T							Yes No
	AO	T							Yes No
	AP								Yes No
	1	o	THER (Includin	a Author. T	Citle, Date, Per	Hinent Page	a. etc	. \	
Q	AR	10	Hunskaar, S.	, et al., "	Formalin test in urosci. Methods l	ı mice, a u	seful	technique fo	
	Iwasaki, Y., et al., "CNQX prevents spinal motor neuron death following scia nerve transection in newborn rats," J. Neuro Sci. 134:21-25, Elsevier Science B (1995)								
	AT	10		inal nerve	experimental mod ligation in the				
EXAMINER	-	B	1				DATE (CONSIDERED	
EXAMINER:	Initial	if r	eference consi	dered, whet	ther or not cita	tion is in	confor	mance with	MPEP 609.

Page 11 of 20



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE August 21, 2003	GROUP 1614

. P	DO AA AB AC AD AE AF	OCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE		
. P	AB AC AD AE	·							
. P	AC AD AE		1	1		ļ			
	AD AE								
	AE								
. P			ļ						
	A F		 			ļ <u>.</u>			
	-					ļ	<u> </u>		
	AG								
A	AH		ļ						
	AI		ļ				ļ		
·	AJ	 	ļ						
A	AK		ļ						
·			POREIGN	PATENT DOCUMENTS			T		
EXAMINER INITIAL	DC	CUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
Д.	AL						Yes No		
۾ ا	AM						Yes No		
4	AN						Yes No		
<i>p</i>	AO						Yes No		
,	AP						Yes No		
· · · · · · · · · · · · · · · · · · ·		OTHER (Includin	g Author.	Title, Date, Pertin	ent Pages, etc	.)			
B A	R <u>11</u>	Kingery, W.S	., "A crit:	ical review of cont mplex regional pair	crolled clinica	al trials fo	or peripheral 139, Elsevier		
2.5	s 11	Kudoh, A., et al., "Effect of Carbamazepine on Pain Scores of Unipolar Depressed Patients with Chronic Pain: A Trial of Off-On-Off-On Design," Clin. J. Pain 14:61-65, Lippincott-Raven Publishers (1998)							
A ^r	т 11	Low, P.A., ar 280:1863-186	nd Dotson, 4, The Amer	R.M., "Symptomatic rican Medical Assoc	Treatment of P iation (Decembe	ainful Neuro er 1998)	ppathy," JAMA		
EXAMINER		31		<u>.</u>	DATE (CONSIDERED			

Page 12 of 20



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE August 21, 2003	GROUP 1614

				U.S.	PATENT DOCUMENTS					
EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE		
	AA									
	AB									
	AC									
	AD									
•	AE	<u> </u>		ļ				<u> </u>		
	AF			<u> </u>			J	<u> </u>		
	AG						<u> </u>			
	AH									
	AI						<u> </u>			
•	AJ									
	AK	1								
•				FOREIGN	PATENT DOCUMENTS					
EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
	AL							Yes No		
	AM							Yes No		
	AN							Yes No		
	AO							Yes No		
	AP		 					Yes No		
		0	THER (Includin	q Author,	Title, Date, Perti	lnent Pages, etc				
Q	AR	12	Lunardi, G.,	et al., "(Clinical effectiver	ness of lamotric	ine and pla	sma levels in 48:1714-1717,		
	AS	<u>12</u>	Magnus, L., "Nonepileptic Uses of Gabapentin," Epilepsia 40(Suppl. 6):S66-S72, Lippincott Williams & Wilkins (October 1999)							
	AT 12 Nicholson, B., "Gabapentin use in neuropathic pain syndromes," Dolor 14:243-250 Publicaciones Permanyer (1999)									
EXAMINER		-	Buil			DATE	CONSIDERED	>		
EXAMINER: I Draw line th	nitial rough	if r	eference consi ion if not in	dered, whe	ther or not citati e and not consider	ion is in conforced. Include co	mance with	MPEP 609. form with		

Page 13 of 20



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE August 21, 2003	GROUP 1614

AA AB AB AC AC AD AC AD AC AD AC AC AC AD AC					# C D	Maria Domina	· · · ·			
INITIAL DOCUMENT NUMBER DATE NAME CLASS SUB-CLASS FILING DATE AB AB AC AC AD AD AB AB AB AB AC AC AD AD AB					1 0.s. p	ATENT DOCUMENTS		Ī	T	
AB AC AD AD AE AF AF AG AN AI AI AI AX FOREIGN PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATIC Y AM AN AN AN AN AN AN AN AN AN	EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
AC AD AB AE AF AG AH AI AI AJ AN BEXAMINER INITIAL AN AN AN AN AN AN AN AN AN		AA								
AB AE AF AG AF AG AH AI AI AX BOCUMENT NUMBER DATE COUNTRY AL AM AN AN AN AN AN AN AN AN AN		AB_								
AR AF AG AH AI AJ AX BEXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATIC YEAR AN AN AN AN COUNTRY CLASS COUNTRY CLASS COUNTRY CLASS COUNTRY CLASS COUNTRY CLASS CLASS COUNTRY CLASS CLASC CLASS CLASC CLASS CLASC CLASS CLASC CLASS CLASC CLASS CLASC CLASC CLASC CLASC		AC								
AE AF AG AH AI AI AJ AK FOREIGN PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATIC AL AM AN AN AN AN AN AN AN AN AN		AD								
AR AR OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Ohizumi, Y., et al., "Specific Inhibitors of ['H] Saxitoxin Binding to Skelet. Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker," (1986) AS 13 Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. AP Pain 13:251-255, Lippincott-Raven Publishers (1997) AT 13 Rosener, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States, Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)	•	AE								
AH AI AJ AJ AX FOREIGN PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATIC AL AM AN AN AN AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Ohizumi, Y., et al., "Specific Inhibitors of ['H] Saxitoxin Binding to Skelet, Biol. Chem. 261:6149-6152, The American Society of Biological Chemists, Inc. (1986) AS 13 Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. Apain 13:251-255, Lippincott-Raven Publishers (1997) AT 13 Rosener, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States, Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)		AF								
POREIGN PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATIC AL YY AN YOU AN YOU AN YOU AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Ohizumi, Y., et al., "Specific Inhibitors of [7H] Saxitoxin Binding to Skelete, Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker," Biol. Chem. 261:6149-6152, The American Society of Biological Chemists, Including 13:251-255, Lippincott-Raven Publishers (1997) AT 13 Rosenberg, J.M., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain," Clin. AT 13 Rosener, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States, Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)	•	AG								
AX AX FOREIGN PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATIC AL AM AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Ohizumi, Y., et al., "Specific Inhibitors of [7H] Saxitoxin Binding to Skelet. Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker," (1986) AS 13 Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. AP Pain 13:251-255, Lippincott-Raven Publishers (1997) AT 13 Rosener, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States, Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)		AH								
POREIGN PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATIC AL AM YOU AM YOU AP OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Ohizumi, Y., et al., "Specific Inhibitors of [7H] Saxitoxin Binding to Skelet. Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker," (1986) AS 13 Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. of Pain 13:251-255, Lippincott-Raven Publishers (1997) AT 13 Rosener, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States, Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)		IA								
POREIGN PATENT DOCUMENTS EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATIC AL YOU AM YOU	·	AJ	<u> </u>							
EXAMINER INITIAL DOCUMENT NUMBER DATE COUNTRY CLASS SUB-CLASS TRANSLATION OF TRAN		AK								
AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Ohizumi, Y., et al., "Specific Inhibitors of ['H] Saxitoxin Binding to Skelett Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker," (1986) AS Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. Pain 13:251-255, Lippincott-Raven Publishers (1997) AT Rosener, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States, Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)	•				FOREIGN	PATENT DOCUMENTS			<u>—</u> .	
AN	EXAMINER									
AN	INITIAL	-	DOC	UMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
AN AN OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Ohizumi, Y., et al., "Specific Inhibitors of ['H] Saxitoxin Binding to Skelet, Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker," (1986) AS 13 Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. (1986) AT 13 Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. (1986) AT 13 Rosener, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States, Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)		AL							Yes No	
AR OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Ohizumi, Y., et al., "Specific Inhibitors of [3H] Saxitoxin Binding to Skelett. Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker," a Biol. Chem. 261:6149-6152, The American Society of Biological Chemists, Inc. (1986) AS 13 Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. Apain 13:251-255, Lippincott-Raven Publishers (1997) AT 13 Rosner, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States, Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)		AM							Yes No	
OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Ohizumi, Y., et al., "Specific Inhibitors of ['H] Saxitoxin Binding to Skelet: Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker," Biol. Chem. 261:6149-6152, The American Society of Biological Chemists, Inc. (1986) AS 13 Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. Pain 13:251-255, Lippincott-Raven Publishers (1997) AT 13 Rosener, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States, Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)				 					Yes	
OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Ohizumi, Y., et al., "Specific Inhibitors of [3H] Saxitoxin Binding to Skelette Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker," a Biol. Chem. 261:6149-6152, The American Society of Biological Chemists, Inc. (1986) AS 13 Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. Pain 13:251-255, Lippincott-Raven Publishers (1997) AT 13 Rosner, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States, Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)	······································		1		 				No Yes	
OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Ohizumi, Y., et al., "Specific Inhibitors of [3H] Saxitoxin Binding to Skeleta Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker," (1986) AS 13 Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. (1986) AT 13 Rosener, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States, Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)		AO							No Yes	
Ohizumi, Y., et al., "Specific Inhibitors of [3H] Saxitoxin Binding to Skelet: Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker," (Biol. Chem. 261:6149-6152, The American Society of Biological Chemists, Inc. (1986) AS 13 Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. (Pain 13:251-255, Lippincott-Raven Publishers (1997) AT 13 Rosner, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States, Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)		AP	<u> </u>						No	
Muscle Sodium Channels by Geographutoxin II, a Polypeptide Channel Blocker, " a Biol. Chem. 261:6149-6152, The American Society of Biological Chemists, Inc (1986) AS 13 Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. Pain 13:251-255, Lippincott-Raven Publishers (1997) AT 13 Rosner, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States, Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)		٦	O':	THER (Includin	g Author, T	itle, Date, Pertine	ent Pages, etc	.)		
Pain 13:251-255, Lippincott-Raven Publishers (1997) Rosner, H., et al., "Gabapentin Adjunctive Therapy in Neuropathic Pain States, Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)	à	AR	13	Muscle Sodium Biol. Chem.	m Channels h	y Geographutoxin I	I, a Polypept	ide Channel	Blocker, " J.	
Clin. J. Pain 12:56-58, Lippincott-Raven Publishers (1996)		AS	13	Rosenberg, J.M., et al., "The Effect of Gabapentin on Neuropathic Pain," Clin. J. Pain 13:251-255, Lippincott-Raven Publishers (1997)						
DATE CONSIDERED		AT	<u>13</u>	Rosner, H., e	et al., "Gab 1 12:56-58,	papentin Adjunctive Lippincott-Raven P	Therapy in No ublishers (19	europathic I	Pain States,"	
	EXAMINER		1	1			DATE (CONSIDERED		
P	EXAMINER:	nitial	if r	eference consi	dered, whet	her or not citation	is in confor	mance with	MPEP 609.	

Page 14 of 20



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE August 21, 2003	GROUP 1614

U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE	
	AA								
	AB								
	AC								
	AD			<u> </u>					
•	AE		 						
	AF								
	AG	1					ļ		
	AH	.				<u> </u>			
<u></u>	AI								
	AJ	 					ļ		
	AK	J						<u></u>	
•	1	T		POREIGN P	ATENT DOCUMENTS				
EXAMINER INITIAL		DOCI	JMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
	AL							Yes No	
	AM							Yes No	
	AN						i	Yes No	
	AO							Yes No	
	AP							Yes	
	125		THER (Includin	a Author Ti	tle, Date, Pertinen	t Pages ets	\	No	
	T	T	T (Including	g Author, II	tie, Date, Fertinen	c rayes, ecc	:/		
	AR 14 Rowbotham, M., et al., "Gabapentin for the Treatment of Postherpetic Neuralgia, JAMA 280:1837-1842, The American Medical Association (December 1998)						: Neuralgia," 3)		
Sheardown, M.J., et al., "AMPA, but not NMDA, receptor antagonism neuroprotective in gerbil global ischaemia, even when delayed 24 h," Eur. Pharmacol. 236:347-353, Elsevier Science Publishers B.V. (1993)						ntagonism is h," Eur. J.			
3	AT	14	Sist, T.C., et al., "Experience With Gabapentin for Neuropathic Pain in the Heand Neck: Report of Ten Cases," Reg. Anesth. 22:473-478, The American Society (Regional Anesthesia (1997)						
EXAMINER	1	B				DATE	CONSIDERED		
EXAMINER: Draw line th	Initial prough	if r	eference consi ion if not in	dered, wheth conformance	er or not citation and not considered.	is in confor Include co	mance with py of this		





FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE August 21, 2003	GROUP 1614

				U.S.	PATENT DOCUMENTS	 	·	
EXAMINER INITIAL		DOC	UMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
	AB							
	AC							
	AD							ļ
•	AE							<u> </u>
	AF							
•	AG			 				
	AH	-		<u> </u>			 	
•	AI	+						
	AJ			1			<u> </u>	
	AK							I
				FOREIGN	PATENT DOCUMENTS			
EXAMINER INITIAL	ľ	DOC	UMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATIO
	AL							Ye N
								Ye
	AM	+		ļ				1
	AN							Y∈ N
	AO							Ye
	AP							Ye N
OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Solaro, C., et al., "A patient with multiple sclerosis and Down's syndrome w a rare paroxysmal symptom at onset," Eur. J. Neurol. 6:505-507, Lippinc Williams & Wilkins. (July 1999)						1		
						syndrome wit , Lippincot		
	Stys, P.K., et al., "Ionic Mechanisms of Anoxic Injury in Mammalian CNS Whit Matter: Role of Na' Channels and Na'—Ca² Exchanger," J. Neurosci. 12:430-439 Society for Neuroscience (1992)							
Taylor, C.P., et al., "Na channels as targets for neuroprotective drugs," Tren Pharmacol. Sci. 16:309-316, Elsevier Science Ltd. (1995)								
EXAMINER	<u>ਦ</u>	Bn				DATE (CONSIDERED	
raw line the	hrough	citat	eference consi ion if not in pplicant.	dered, whe	ther or not citation	on is in confor	mance with	MPEP 609.

								Page 16 of 20	
MADENANTA					ATTY. DOCKET NO. 1483.0370003/JMC	/THN	APPLICATION 10/644,783	NO.	
			PTO-1449		APPLICANT Nancy C. LAN				
INF	ORMATIO	ON DIS	CLOSURE STATEM	MENT	FILING DATE August 21, 2003		GROUP 1614		
				U.S. PAT	ENT DOCUMENTS				
EXAMINER INITIAL		DOCT	JMENT NUMBER	DATE	NAME	CLAS	SUB-CLASS	FILING DATE	
	AA								
	AB								
	AC								
	AD								
	AE							ļ <u>.</u>	
	AF							 	
	AG						ļ	<u> </u>	
	AH	<u> </u>						ļ	
ļ	AI	 		ļ				 	
	AJ								
-	AK			L					
				FOREIGN P	ATENT DOCUMENTS			T	
·EXAMINER INITIAL		DOC	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
	AL-							Yes No	
	АM							Yes No	
	AN							Yes No	
	AO							Yes No	
	AP							Yes No	
The second section of the section of the section of the second section of the section of t	1	0'	THER (Including	g Author, Ti	tle. Date. Pertine	ent Pages, et	te.)		
(Ja	OTHER (Including Author, Title, Date, Pertinent Pages, etc.) AR Verdoorn, T.A., et al., "Functional Properties of Recombinant Rat GABA, Receptor Depend upon Subunit Composition," Neuron 4:919-928, Cell Press (1990)								
	AS	<u>16</u>	Victor, M., et al., "Chapter 352: Diseases of the Cranial Nerves," in Harrison's Principles of Internal Medicine 11:2035-2040, Braunwald, et al., eds., McGraw-Hill Inc. (1987)						
	Wamil, A.W., and McLean, M.J., "Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture," Epilepsy Res. 17:1-1 Elsevier Science B.V. (1994)								
EXAMINER						DATE	CONSIDERED		
Draw line th	hrough	citat	ion if not in	dered, wheth conformance	er or not citation	n is in conf d. Include	ormance with	MPEP 609. form with	
next commun::ODMA\MHODM	ication	to A	pplicant.						

Page 17 of 20

OIPE	
" " " " " " " " " " " " " " " " " " "	١
NOV 2 5 2003 =	•
TRADENSON	

FORM PTO-1449

	INFORMATION	DISCLOSURE	STATEMENT
--	-------------	------------	-----------

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

	August 21, 2003 1614							
				U.S. PA	TENT DOCUMENTS			
EXAMINER INITIAL		DOCI	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DAT
	AA							
	AB	<u> </u>		ļ			-	
	AC	-		<u> </u>				
	AD	-		<u> </u>			 	
	AE	-		 				
	AF AG	+	·	 			 	
	AH	+						
	AI	 	·				i	
	AJ							
	AK							
				FOREIGN P	ATENT DOCUMENTS		·	
XAMINER NITIAL	<u> </u>	DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATIO
	AL							Y
	AM							Y
	AN							Y
	AO							Y
	AP			,				Y
	IAF	07	THER (Includin	ng Author, Ti	tle, Date, Pertine	nt Pages, etc	=.)	· · · · · · · · · · · · · · · · · · ·
Wrathall, J.R., et al., "Amelioration of Functional Deficits from Spins Trauma with Systemically Administered NBQX, an Antagonist of Non-N-me aspartate receptors," Exp. Neurology 137:119-126, Academic Press, Inc. (Yoon, M.H., and Yaksh, T.L., "Evaluation of Interaction between Gabapen Ibuprofen on the Formalin Test in Rats," Anesthesiology 91:1006-1013, Lip Williams & Wilkins, Inc. (October 1999)					n-N-methyl-			
(3)	AT	17	Dialog File 3 DE 198 02 32		n No. 12613976, Der nt AN3)	went WPI Engl	ish language	abstract f
XAMINER		B	1		•	DATE	CONSIDERED	
XAMINER:	Initial	if r	eference cons: ion if not in	idered, wheth	er or not citation	is in confo	rmance with	MPEP 609.

2 5 2003 MADE	(c) 41.30g							
	<u> </u>							Page 18 of 20
CAUCHE	•				ATTY. DOCKET NO. 1483.0370003/JMC/	THN	APPLICATION 10/644,783	NO.
TNI	PODMATT.		PTO-1449 CLOSURE STATE	MENT	APPLICANT Nancy C. LAN			
1111	ORPATIO	JN DIS	CHOSOKE STATE	PIENT	FILING DATE August 21, 2003		GROUP 1614	
				U.S. PA	TENT DOCUMENTS	 :		
EXAMINER	1	T						T
INITIAL	-	DOCU	MENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA	 						
<u></u>	AB	+		ļ	 			
	AC AD	+		 			 	
	AE	+		†	<u> </u>			
· · · · · · · · · · · · · · · · · · ·	AF	 		1			 	
	AG			-				
•	АН							
	AI							
	AJ	ļ						
	AK				<u> </u>			
		1		FOREIGN P	ATENT DOCUMENTS		·	
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	CITE OF NCC	TO A NOV A TO A
INTITAL	 	1000	MENT NOMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL	ļ						No
	AM	İ						Yes
	- Air	†					 	No
	AN	<u> </u>						Yes No
	AO			1				Yes
	120	1	· · · · · · · · · · · · · · · · · · ·					No
	AP							Yes No
		OT	HER (Includin	g Author, Ti	tle, Date, Pertinen	t Pages, et	c.)	
8	AR	18	List of abst	racts concern	ning SCRIP 1773:14	(1992) provi	ded by clien	nt
	AS	18 List of abstracts concerning SCRIP 1870:8 (1993) provided by client						
(3)	AT 18 STN Database, Accession No. 1998:9096, "Warner-Lambert forecasts 35% earning growth," SCPTP 2330:8 (1998)						35% earnings	
EXAMINER			D 1			DATE	CONSIDERED	
EXAMINER: I	nitial	if te	ference consi	tered whether	er or not citation	is in confo	7 4 8/05	MDED 600
Draw line the next communi	rough o	to Ap	on if not in plicant.	conformance a	and not considered.	Include c	opy of this	form with

Page 19 of 20

<i>f.</i>	OIPE
	CD 25 2003
1	TRADEWOLD !

· FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 1483.0370003/JMC/THN	APPLICATION NO. 10/644,783
APPLICANT Nancy C. LAN	
FILING DATE	GROUP

EXAMINER								
EXAMINER				U.S. P.	ATENT DOCUMENTS			
INITIAL		DOCUM	ENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA							
	AB							
	AC		· · · · · · · · · · · · · · · · · · ·					
	AD							
	AE							
·	AF						ļ	
	AG							
	AH							
	AI							
	AJ							
	AK						<u></u>	
				FOREIGN	PATENT DOCUMENTS		T	1
EXAMINER INITIAL		DOCUM	ENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL							Ye N
	AM							Ye N
	AN		 					Ye N
	AO							Ye:
	AP							Ye:
	AF	ОТН	IRR (Include	ng Author. T	itle, Date, Pertinen	t Pages, etc		1
5	AR	19	United Stat	es Applicatio	on No. 60/126,553, Ho	genkamp <i>et a</i>	al., filed Ma	arch 26, 199
	AS	19	Attal, N., Neurotherap	"Antiepilept eutics 1:199	ic drugs in the treat -206, Future Drugs L	ment of neur td. (2001)	opathic pai	n," Exp. Rev
6)	AT				athic Pain: New Ins: 04,107-110,113-114, T			
EXAMINER			3			DATE	CONSIDERED NATION	

Page 20 of 20



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

	APPLICATION NO. 10/644,783		
APPLICANT Nancy C. LAN			
FILING DATE	GROUP		

				August 21, 2003	2003 1614					
U.S. PATENT DOCUMENTS										
EXAMINER INITIAL		DOCI	JMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE		
	AA									
	AB									
	AC									
	AD									
	AE	<u> </u>								
•	AF									
	AG									
	AH	ļ								
	AI	ļ								
	AJ	 								
•	AK	<u> </u>				l	·			
FOREIGN PATENT DOCUMENTS										
EXAMINER INITIAL		DOCU	MENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION		
	AL							Yes No		
	AM							Yes No		
	AN							Yes No		
	AO							Yes No		
	AP							Yes No		
	•	01	HER (Including	Author, Tit	le, Date, Pertinent Pag	es, etc	.)			
OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Borowicz, K.K., et al., "Effect of Gabapentin on the Anticonvulsant Activity of Antiepileptic Drugs against Electroconvulsions in Mice: An Isobolographic Analysis," Epilepsia 43:956-963, Blackwell Publishing, Inc. (2002)										
	AS									
	АТ									
EXAMINER		Br				DATE CONSIDERED				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

::ODMA\MHODMA\SKGF_DC1;197764;1